[go: up one dir, main page]

AU2001249393A1 - Pharmaceutical comprising an agent that blocks the cell cycle and an antibody - Google Patents

Pharmaceutical comprising an agent that blocks the cell cycle and an antibody

Info

Publication number
AU2001249393A1
AU2001249393A1 AU2001249393A AU4939301A AU2001249393A1 AU 2001249393 A1 AU2001249393 A1 AU 2001249393A1 AU 2001249393 A AU2001249393 A AU 2001249393A AU 4939301 A AU4939301 A AU 4939301A AU 2001249393 A1 AU2001249393 A1 AU 2001249393A1
Authority
AU
Australia
Prior art keywords
antibody
pharmaceutical
blocks
agent
cell cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249393A
Inventor
Vincent Clark Knick
Julie Beth Stimmel
Linda Margarite Thurmond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2001249393A1 publication Critical patent/AU2001249393A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001249393A 2000-03-22 2001-03-22 Pharmaceutical comprising an agent that blocks the cell cycle and an antibody Abandoned AU2001249393A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19133600P 2000-03-22 2000-03-22
US60191336 2000-03-22
PCT/US2001/009368 WO2001070268A1 (en) 2000-03-22 2001-03-22 Pharmaceutical comprising an agent that blocks the cell cycle and an antibody

Publications (1)

Publication Number Publication Date
AU2001249393A1 true AU2001249393A1 (en) 2001-10-03

Family

ID=22705070

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249393A Abandoned AU2001249393A1 (en) 2000-03-22 2001-03-22 Pharmaceutical comprising an agent that blocks the cell cycle and an antibody

Country Status (4)

Country Link
EP (1) EP1265635A1 (en)
JP (1) JP2003527441A (en)
AU (1) AU2001249393A1 (en)
WO (1) WO2001070268A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
WO2003028696A2 (en) * 2001-10-03 2003-04-10 Celator Technologies Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
CN100422316C (en) 2002-05-24 2008-10-01 先灵公司 Human neutralizing antibodies against insulin-like growth factor receptor (IGFR)
AT413486B (en) 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie USE OF AN ANTIBODY DIRECTED AGAINST LEWIS ANTIGENE
DK2949658T3 (en) 2003-03-03 2018-10-01 Dyax Corp Peptides that specifically bind HGF receptor (cMet) and uses thereof
BRPI0413876A (en) 2003-08-29 2006-10-24 Pfizer thienopyridin-phenylacetamides and their derivatives useful as antiangiogenic agents
CA2545755A1 (en) 2003-11-12 2005-05-26 Schering Corporation Plasmid system for multigene expression
PE20050928A1 (en) 2003-11-21 2005-11-08 Schering Corp THERAPEUTIC COMBINATIONS OF ANTI-IGFR1 ANTIBODY
NZ547009A (en) 2003-12-23 2009-09-25 Pfizer Novel quinoline derivatives
ES2356830T3 (en) 2004-12-03 2011-04-13 Schering Corporation BIOMARCATORS FOR PRESELECTION OF PATIENTS FOR ANTI-IGF-1R THERAPY.
RU2406760C3 (en) 2005-05-09 2017-11-28 Оно Фармасьютикал Ко., Лтд. HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMABLE DEATH 1 PROTECTION (PD-1) AND METHODS OF CANCER TREATMENT USING ANTI-PD-1-ANTI-BODY, INDEPENDENTLY OR IN COMBINATION WITH OTHER IMMUNETURAH AND I And I And I And I, In The Combine, I And I Do Not Allocate To Them, Combined With Other Overarching
KR101832133B1 (en) * 2011-10-20 2018-02-27 주식회사 차바이오텍 Method for the Isolation and Proliferation of Primary Lung Cancer Cells
KR102043603B1 (en) * 2012-10-12 2019-11-12 주식회사 차바이오텍 Isolation of lung cancer cells and proliferation thereof using suspension culture method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884418B1 (en) * 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO2001007082A1 (en) * 1999-07-23 2001-02-01 Glaxo Group Limited Combination of an anti-ep-cam antibody with a chemotherapeutic agent

Also Published As

Publication number Publication date
EP1265635A1 (en) 2002-12-18
JP2003527441A (en) 2003-09-16
WO2001070268A1 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
AU2001249393A1 (en) Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
AU2002225681A1 (en) Yeast-dentritic cell vaccines and uses thereof
MXPA03005923A (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines.
AU2002225356A1 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
AU2001227586A1 (en) Application report and method for creating the same
AU2002229534A1 (en) Particles with opalescent effect
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2001213236A1 (en) Mini-cyclone biocollector and concentrator
AU2001213042A1 (en) Kneading device and forming device
AU2002255451A1 (en) Procaryotic libraries and uses
GB9927332D0 (en) Novel antibody and uses thereof
EP1281353A4 (en) Pulsometer and measuring system comprising the same
AU2001240637A1 (en) Novel imidazotriazinones and the use thereof
EP1151667A3 (en) Plant-activating agent
AU2002211717A1 (en) Stresscopins and their uses
AU2001272011A1 (en) Siderophores-producing bifidobacteria thereby and uses thereof
HUP0300334A3 (en) Pharmaceutical preparations and their manufacture
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2001229770A1 (en) Improved research and development process
AU2001229439A1 (en) Bioconjugates and uses thereof
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU2002223313A1 (en) Protease inhibitors and their pharmaceutical uses
AU2001274535A1 (en) Hydroxyformamidine derivatives and medicines containing the same
AU1417701A (en) Soluble t cell receptor protein and method of constructing the same
AU2000231564A1 (en) Phosphororganic compounds and the use thereof